Comparing the current results to its competitors, Abeona Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 697.48 % year on year. The sales growth was above Abeona Therapeutics Inc 's competitors' average revenue growth of 16.12 %, achieved in the same quarter.
Abeona Therapeutics Inc , slower than the average decrease reported by the company's competitors of -33.95 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -33.95 %
Abeona Therapeutics Inc 's Comment on Competition and Industry Peers
The competitive landscape includes companies currently engaged in gene therapy as well as those not yet focused on cell and gene therapies but with potential to develop relevant treatments. Many competitors, alone or with strategic partners, possess greater financial, technical, and human resources, along with more experience in discovery, development, regulatory approval, and commercialization of product candidates. These competitors may achieve approvals and market acceptance more successfully, which could render the company's treatments obsolete or non-competitive. Mergers and acquisitions within the biotechnology and pharmaceutical industries may concentrate resources among fewer competitors. Additionally, competitors vie for personnel recruitment, clinical trial site establishment, and acquisition of complementary technologies. Smaller or early-stage companies may also present significant competition, particularly through collaborations with larger companies. The company expects to face intense and increasing competition as new products enter the market.
Due to outstanding performance in Overall company, revenue grew by 697.48 % Abeona Therapeutics Inc improved its market share, to approximately 0.29 %.
April 29, 2025
for CSIMarket.com The recent approval of ZEVASKYN (prademagene zamikeracel) by the U.S. Food and Drug Administration (FDA) marks a significant advancement in the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare and debilitating skin disorder with no existing cure. RDEB is characterized by extreme fragility of the skin and mucous membranes, leading to blistering and severe complications. ZEVASKYN is notable as it represents the first and only cell-based gene therapy targeting this condition, addressing a critical unmet need for affected patients and their families.Gene therapy has emerged as a revolutionary approach, offering potential long-term benefits by modifying genetic or cellu...
Portage Biotech Inc.'s business model involves the identification and development of innovative therapeutics and healthcare solutions, leveraging a unique portfolio of biotechnology companies and their technologies.
Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company's revenue streams primarily come from partnerships, licensing agreements, and product sales.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Sources:
Abeona Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Abeona Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
